These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7583819)

  • 1. Study assigns dollar value to alteplase-streptokinase debate.
    Am J Health Syst Pharm; 1995 Aug; 52(15):1600. PubMed ID: 7583819
    [No Abstract]   [Full Text] [Related]  

  • 2. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
    Barradell LB; Goa KL
    Pharmacoeconomics; 1995 Nov; 8(5):428-59. PubMed ID: 10172669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is alteplase (t-PA) more cost-effective than streptokinase?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):427-8. PubMed ID: 10172065
    [No Abstract]   [Full Text] [Related]  

  • 4. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting.
    Pelc A; Dardenne J; Frelon JH; Hanania G
    Pharmacoeconomics; 1997 Jun; 11(6):595-605. PubMed ID: 10173031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic treatment. Streptokinase is more economical than alteplase.
    Mucklow JC
    BMJ; 1995 Dec; 311(7018):1506. PubMed ID: 8520368
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD; Bronskill S; Goel V
    Can J Cardiol; 1993; 9(6):553-8. PubMed ID: 8221354
    [No Abstract]   [Full Text] [Related]  

  • 9. Who uses streptokinase vs alteplase (t-PA), and why?
    Sanchez LA
    Pharmacoeconomics; 1992 Nov; 2(5):428-9. PubMed ID: 10172066
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
    Califf RM; Stump D; Topol EJ; Mark DB
    Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606
    [No Abstract]   [Full Text] [Related]  

  • 11. Trials of the European Working Party on streptokinase and of the European Cooperative Study Group on alteplase in patients with acute myocardial infarction. European Investigators.
    Verstraete M
    J Interv Cardiol; 1995 Dec; 8(6):611-21. PubMed ID: 10172727
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece.
    Maniadakis N; Kaitelidou D; Siskou O; Spinthouri M; Liaropoulos L; Fragoulakis B; Hatzikou M; Alexopoulosi D
    Hellenic J Cardiol; 2005; 46(3):212-21. PubMed ID: 15981557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic therapy for acute myocardial infarction.
    Clem JR
    S D J Med; 1994 Jan; 47(1):27-8. PubMed ID: 8122094
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrated systems may have economic incentive for using alteplase in stroke patients.
    Am J Health Syst Pharm; 1998 Jun; 55(12):1248. PubMed ID: 9640463
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D
    Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating myocardial infarction in the post-GUSTO era. A US perspective.
    Mark DB
    Pharmacoeconomics; 1996 Jun; 9(6):473-7. PubMed ID: 10172705
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic therapy in the elderly. Pharmacoeconomic considerations.
    Ramanathan K; Ellis CJ; White HD
    Drugs Aging; 1996 Apr; 8(4):237-44. PubMed ID: 8920173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thrombolytic therapy in acute myocardial infarction].
    Pedersen TR
    Tidsskr Nor Laegeforen; 1994 May; 114(14):1646-7. PubMed ID: 8079271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.